TOPICS

April

- Basic agreement reached between SBI Pharmaceuticals Co., Ltd. and the government of Bahrain to promote the 5-ALA business
- SBI Mortgage Co., Ltd. listed on the KOSPI Market of the Korea Exchange

May

- The First SBI Global Strategic Conference, attended by representatives of the SBI Group's overseas partners, was held in Hong Kong
- Implemented a buy-back of 377,857 shares at a cost of approximately ¥2.0 billion (buy-back period: May 25 to June 13, 2012)
- SBI FXTRADE Co., Ltd., a foreign exchange trading company, commenced business
- Jointly established a fund with Edelweiss Financial Services Ltd., an integrated financial services company in India, to invest in small and mid-cap listed companies in India
- Reached a basic agreement with Netherlands Development Finance Company Financierings-Maatschappij voor Ontwikkelingslanden (FMO) to jointly establish a fund to invest primarily in financial institutions in Asia

June

- Established SBI Capital Management Co., Ltd. as an intermediate holding company for the Asset Management Business and SBI FINANCIAL SERVICES Co., Ltd. as an intermediate holding company for the Financial Services Business
- Implemented reorganization of face-to-face sales businesses centering on SBI MONEY PLAZA Co., Ltd. and transferred the face-to-face division of SBI SECURITIES Co., Ltd. to SBI MONEY PLAZA Co., Ltd.

July

- Established PT. Strategi Bisnis Infoyasa, a joint venture company involved in the financial products comparison service business in Indonesia, together with PT. CORFINA MITRAKREASI
- Completed the transference of the Company's stake in the Wall Street Journal Japan K.K. to Dow Jones & Company, Inc. of the U.S.

September

- SBI Japannext Co., Ltd. converted from an equity-method affiliate to a wholly owned subsidiary
- Transferred all shares of SBI Capital Solutions Co., Ltd. and the SBI Group's equity interest in funds managed by it

2012

Apr

May

Jun

Sep



Signing ceremony between SBI Pharmaceuticals Co., Ltd. and the government of Bahrain



The first SBI Global Strategic Conference held in Hong Kong



A branch of SBI MONEY PLAZA Co., Ltd. inherited face-to-face sales businesses from SBI SECURITIES Co., Ltd.



An office of the newly converted wholly owned subsidiary, SBI Japannext Co., Ltd.

October

- Implemented a 10-for-1 stock split
- SBI Pharmaceuticals Co., Ltd. established the Bahrain Representative Office
- SBI Searchina Co., Ltd. and SBI Asset Management Co., Ltd. were made subsidiaries of Morningstar Japan K.K.

November

- Reached an agreement to acquire a 20% stake in photonamic GmbH & Co. KG, which engages in pharmaceutical development using 5-ALA in Europe
- SBI Insurance Co., Ltd. received three stars, the highest rank, in Support Portal (Official Website) Category of HDI-Japan's Call-Center Contact Ranking
- Subscribed to unsecured convertible bonds with stock acquisition rights issued by WebCrew Inc. and transferred a portion of shares in SBI Insurance Co., Ltd. to WebCrew

December

- SBI AXES Co., Ltd. listed on the KOSDAQ Market of the Korea Exchange, and established a Korean subsidiary
- Quark Pharmaceuticals, Inc. was made a subsidiary of SBI Biotech Co., Ltd.
- The investment fund management company established with Shanghai Yidian Holding (Group) Company became the first non-Chinese company to be approved under the Renminbi Qualified Foreign Limited Partner (RQFLP) program

January

- SBI Sumishin Net Bank, Ltd. ranked No. 1 in the banking industry for the fourth consecutive year in the 2012 JCSI (Japan Customer Satisfaction Index)
- SBI SECURITIES Co., Ltd. received three stars, the highest rank, in HDI-Japan's Call-Center Contact Ranking, which rates company call centers, and Support Portal Ranking, which rates websites, in a row

March

- SBI Pharmaceuticals Co., Ltd. signed a basic agreement with Arabian Gulf University of Bahrain for the joint clinical research concerning diabetes and reached a basic agreement to conduct joint clinical research with the Royal College of Surgeons in Ireland-Medical University of Bahrain.
- SBI Pharmaceuticals Co., Ltd. signed an agreement with Dawani Group Holdings of Bahrain to establish a joint venture company to market 5-ALA products in Bahrain
- SBI Pharmaceuticals Co., Ltd. reached basic agreements with Mumtalakat Holding Company, a government fund in Bahrain, and The Bahrain Development Bank concerning collaboration in the 5-ALA business in Bahrain, principally in the pharmaceuticals field
- SBI Pharmaceuticals obtained manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for ALAGLIO[®], an orally administered in vivo diagnostic agent used during the surgical resection of malignant glioma, as the first pharmaceutical agent made using 5-ALA
- Acquired shares of Hyundai Swiss Savings Bank and made it a consolidated subsidiary
- Acquired all shares of IKIIKI SEDAI and made it a consolidated subsidiary
- Transferred the Company's entire stake in SBI Credit Co., Ltd.

2013

Oct

Dec

Jan

Mar



The site of the SBI Pharmaceuticals Co., Ltd. Bahrain Representative Office



SBI AXES Co., Ltd. listed on the KOSDAQ Market of the Korea Exchange



SBI SECURITIES Co., Ltd. received three stars, the highest rank, in HDI-Japan's Call-Center Contact Ranking



SBI Pharmaceuticals Co., Ltd. reached basic agreement with Mumtalakat Holding Company concerning on collaboration in the 5-ALA business



For the latest topics, see "News Release" at our website: (http://www.sbigroup.co.jp/english/news/)